At Astria, we are focused on developing differentiated therapeutics for allergic and immunologic diseases. Our pipeline represents our vision to improve patients’ quality of life by creating first-choice treatments based on established mechanisms designed to reduce disease and treatment burden.
Safety and efficacy for our product candidates have not been established. There is no guarantee that the outcome of these studies will be positive or result in the approval by a Health Authority.